作者: Alessandra Tedeschi , Marco Montillo , Elena Strocchi , Anna Maria Cafro , Elisabetta Tresoldi
DOI: 10.1007/S00280-006-0332-4
关键词: Medicine 、 Refractory 、 Acute lymphocytic leukemia 、 Cerebrospinal fluid 、 Idarubicin 、 Pharmacology 、 Metabolite 、 Cytarabine 、 Pharmacokinetics 、 Antimetabolite
摘要: Objective High dose (HD) Ara-C combined with a single HD idarubicin (IDA) is an efficient and safe salvage regimen for patients refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies. No data are available on the pharmacokinetics of IDA after rapid intravenous infusion. An open pharmacokinetic clinical study was performed to evaluate antileukemic efficacy, investigate presence its reduced metabolite idarubicinol (IDAol) in cerebrospinal fluid (CSF) treated HD-IDA.